Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL

This phase 2 study was conducted to prospectively evaluate how clinical and biological factors correlate with outcome in patients with treatment-naive (TN) and relapsed (R) chronic lymphocytic leukemia (CLL) treated with lenalidomide and rituximab. Oral lenalidomide 10 mg was administered daily star...

Full description

Saved in:
Bibliographic Details
Published in:Blood Adv
Main Authors: Strati, Paolo, Takahashi, Koichi, Peterson, Christine B., Keating, Michael J., Thompson, Philip A., Daver, Naval G., Jain, Nitin, Burger, Jan A., Estrov, Zeev, O'Brien, Susan M., Kantarjian, Hagop M., Wierda, William G., Futreal, P. Andrew, Ferrajoli, Alessandra
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2019
Subjects:
Lymphoid Neoplasia
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6517659/
https://ncbi.nlm.nih.gov/pubmed/31076409
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019031336
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items